Connecticut Attorney General files lawsuit against McKesson over alleged inflation of prescription drug prices

Connecticut Attorney General Richard Blumenthal (D) on Thursday filed a lawsuit in U.S. District Court in Boston over allegations that prescription drug distributor McKesson conspired to inflate the average wholesale prices of hundreds of brand-name medications in violation of federal racketeering and state consumer protection laws, the AP/Hartford Courant reports.

According to the lawsuit, McKesson conspired with First DataBank and other companies that publish prescription drug prices to increase, fix and maintain AWPs for 400 brand-name medications at 25% more than wholesale acquisition costs, compared with a previous premium of 20%.

Blumenthal said that, because state and federal health care programs base reimbursement rates for prescription drugs on AWPs, physicians, pharmacies and other health care providers that prescribed or dispensed medications distributed by McKesson could increase their profits. He added that state health care programs and residents overpaid by millions of dollars for prescription drugs because of the "illegal and deceptive practices" used by McKesson. Blumenthal said, "The victims of this surreptitious scheme included the patients and taxpayers who were overcharged by companies seeking higher sales and profits," adding, "McKesson exploited publicly funded programs that serve our most vulnerable citizens."

McKesson officials have not reviewed the lawsuit, according to an e-mail from company spokesperson James Larkin. In addition, he wrote that McKesson does not set AWPs or retail prices for prescription drugs paid by health plans or consumers. McKesson has denied similar allegations in other lawsuits, the AP/Courant reports (Collins, AP/Hartford Courant, 5/29).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options